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19th CardioVascular Summit: TCTAP 2014were signiﬁcantly larger than those of the volunteers. Although there was a positive
correlation between body mass index and visceral fat area (r¼0.86, p<0.01), the ration
of visceral fat area to body mass index was also higher in the hospitalized patients
(3.24  1.40 vs 2.11  0.61, p<0.01). Correlations of age to body mass index
(r¼0.09, p¼0.44) and visceral fat area (r¼0.16, p¼0.14) were not signiﬁcant, how-
ever, the ratio of visceral fat area to body mass index had a weak correlation to age
(r¼0.24, p¼0.03).
Conclusion: Hospitalized patients in the cardiology ward had larger visceral fat.
Further investigation is needed to demonstrate clinical usefulness of this novel
technique.
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Yongjun Zhang, Xiaolan Wang
The Sixth People’s Hospital Afﬁliated to Shanghai Jiaotong University, Shanghai,
China
Background: Myocardial infarction is a leading cause of death and disability, with a
direct correlation between infarct size and prognosis. Early reperfusion is an absolute
prerequisite for the survival of ischemic myocardium. However, reperfusion itself may
lead to accelerated and additional myocardial injury beyond that generated by
ischemia alone. Oxygen free radical theory is an important mechanism of ischemia-
reperfusion injury. hydroxyl, which has high High toxicity, can be removed by CAT.
in the stage of reperfusion,endogenous CAT is relative scanty. CAT does not readily
penetrate through membranes,but CAT can penetrate through cell TCTAP A-208
membranes by PEP-1. And PEP-1-CAT has Biological activity.
Methods: 40 Male rats were divided into 5 groups at random, Sham-operated group,
ischemia-reperfusion group(I/R group), PEP-1-CAT-treated group (group1,group2,
group3). 1ml NS were injected via caudal vein in Sham-operated group and ischemia-
reperfusion group, 100mg, 300mg and 500mg PEP-1-CAT were administered via
caudal vein respectively.7 hours later, the left main coronary artery was occluded for
30 minutes followed by a 2-h reperfusion in anesthetized rats, at the end of reperfu-
sion,hemodynamics were measured. Infarct size were measured by TTC staining, LDH,
CK in blood serum and MDA in myocardium were measured according to the manu-
facturer’s protocol. The myocardial cell apoptosis was determined with TUNEL (TdT-
mediated dUTP Nick-End Labeling) method. Immunoﬂuorescent method was used to
detect the expression changes of bcl-2 and bax in rat myocardium of left ventricle.
Results: Compared with I/R group, PEP-1-CAT-treated groups, LVSP anddp/dtmax
were increased(p<0.01), LVEDP were decreased(p<0.01). Cardiac infarct areas
appeared in each group, but the infarct size in PEP-1-CAT fusion protein groups were
signiﬁcantly lower than I/R group (p<0.05 or p<0.01). The myocardial MDA content
LDH and CK release were signiﬁcantly lower in PEP-1-CAT- treated groups than in I/R
group(p<0.01). Under the ﬂuorescent microscope, the apoptotic myocytes demon-
strated brilliant green ﬂuorescence and the percentage of apoptotic myocytes were
decreased signiﬁcantly in PEP-1-CAT-treated groups compared with I/R group
(p<0.01). DAPI marked nucleus demonstrated blue ﬂuorescence when excited under
UV light,whereas the expression of Bcl-2 and Bax protein in the cytoplasm as well as
nucleus membrane demonstrated brilliant green ﬂuorescence, some of which were
merged especially in bcl-2. Compared with I/R group, the drug group markedly
decreased the expression of Bax (p<0.01),the ratio of Bax to Bcl-2 was decent
incidentally.
Conclusion: PEP-1-CAT preconditioning has protective effect on ischemia-reperfu-
sion injury, this may be related with anti-oxidant and anti-apoptosis effect.
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Background: Chronic statin administration may be associated with modestly
increased risk of new-onset type 2 diabetes mellitus (T2DM). However, there were no
data whether there are different inﬂuence on the development of diabetes mellitus
between atorvastatin and simvastatin.
Methods: A total of 877 hyperlipidemia patients received statin and divided into 2
groups according to the type of statins; Atorvastatin group (n¼536) and Simvastatin
group (n¼242). 36-month cumulative incidence of new-onset T2DM were captured
and compared between the two groups.
Results: At baseline, patients in the atorvastatin group had a lower fasting glucose,
HDL-C, ﬁbrinogen, and higher history of angiotensin converting enzyme inhibitorJACC Vol 63/12/Suppl S j April 22–25, 2014 j TCTAP Abstracts/POST(ACEI) use. However, after propensity score matching, the two groups showed no
signiﬁcant difference at baseline. There was no signiﬁcant difference in cumulative
incidence of new-onset T2DM up to 36 months (Figure).
Conclusion: In our study, the cumulative incidence of new-onset T2DM up to 36
months were not different between chronic simvastatin and atorvastatin use.Peripheral Vascular Intervention
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Background: In general, it has been known that hemodialysis was associated with
vascular calciﬁcation and adverse clinical outcomes following endovascular inter-
vention (EVT). Although the success rate of infra-popliteal arterial lesion causing
critical limb ischemia (CLI) is becoming very high; however, the impact of hemo-
dialysis on the major clinical outcomes following successful EVT is not clariﬁed yet.
Methods: This study consisted of 115 consecutive CLI patients (pts) with infra-popliteal
arterial lesion underwent EVT from September 2006 to September 2010. Provisional
stenting was done once the balloon angioplasty outcome is not optimal, mainly by self-
expanding nitinol stents. 1-year clinical outcomes of hemolysis group (n¼89 pts) were
compared with those of non-hemolysis group (n¼26 pts) up to 12 months.
Results: The baseline clinical characteristics were similar between the two groups
except that the combined femoral arterial lesion (61.5% vs. 38.2%) was more frequent
in the hemodialysis group. 1-year repeat revascularization such as TLR, TER was
similar between the two groups. However, the incidence of unknown origin death
(16.7% vs. 0%, p¼0.006) and ostectomy (27.8% vs. 8.1%, p¼0.036) was higher in the
hemodialysis group (table).
Conclusion: In our study, at 1 year, despite of similar incidence of repeat revascu-
larization, the incidence of non-cardiac death and surgical intervention (ostectomy,
amputation, debriment) was higher in the hemodialysis group. Thus, CLI pts on he-
modialysis should be managed by more intensive care.ER/Other Pharmacologic Agents S59
